Saltar al contenido
Merck

SAB4200060

Sigma-Aldrich

Anti-CYLD antibody produced in rabbit

~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution

Sinónimos:

Anti-Cylindromatosis (turban tumor syndrome), deubiquitinating enzyme CYLD, Anti-Ubiquitin carboxyl-terminal hydrolase CYLD, Anti-Ubiquitin specific peptidase like 2, Anti-Ubiquitin thiolesterase CYLD

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

200 μL
478,00 €

478,00 €


Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad

Solicitar un pedido a granel

Seleccione un Tamaño

Cambiar Vistas
200 μL
478,00 €

About This Item

Código UNSPSC:
12352203
NACRES:
NA.41

478,00 €


Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad

Solicitar un pedido a granel

origen biológico

rabbit

conjugado

unconjugated

forma del anticuerpo

affinity isolated antibody

tipo de anticuerpo

primary antibodies

clon

polyclonal

Formulario

buffered aqueous solution

mol peso

antigen ~110 kDa

reactividad de especies

human, rat, mouse

concentración

~1.0 mg/mL

técnicas

immunohistochemistry: 10-20 μg/mL using heat-retrieved formalin-fixed, paraffin-embedded human skin sections and biotin / ExtrAvidin®-Peroxidase staining system
western blot: 1-2 μg/mL using whole extracts of rat and mouse brain

Nº de acceso UniProt

Condiciones de envío

dry ice

temp. de almacenamiento

−20°C

modificación del objetivo postraduccional

unmodified

Información sobre el gen

human ... CYLD(1540)
mouse ... Cyld(74256)
rat ... Cyld(312937)

Descripción general

Anti-CYLD is produced in rabbit using as the immunogen a synthetic peptide corresponding to a fragment of human CYLD conjugated to KLH. Cylindromatosis (CYLD) contains an ubiquitin C-terminal ubiquitin-specific protease (USP) catalytic domain, which is responsible for the removal of ubiquitin chains and three cytoskeleton-associated protein-glycine conserved (CAP-Gly) domains.
CYLD is a tumor suppressor that encodes a deubiquitination enzyme. This enzyme regulates cell growth and survival. Inhibition of CYLD can cause cancers of the skin appendages, namely, multiple trichoepithelioma and familial cylindromatosis . Anti-CYLD antibody is specific for CYLD in humans, rats and mice. The immunizing peptide specifically inhibits the detection of the CYLD band by immunoblotting.

Aplicación

Anti-CYLD antibody can be used in immunohistochemistry (10-20 μg/mL using heat-retrieved, formalin-fixed, paraffin-embedded, human skin sections and biotin / ExtrAvidin® -Peroxidase staining system). This antibody is also suitable for use in immunoblot (approx. 110 kDa) and western blot (1-2 μg/mL using whole extracts of rat and mouse brain).
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)

Acciones bioquímicas o fisiológicas

Cylindromatosis (CYLD) physically interacts with many different proteins and mediates signaling through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and c?Jun N?terminal kinase (JNK) pathways and induces their deubiquitination. It controls cell proliferation and inflammatory responses by NF-κB/JNK-signaling pathways. CYLD regulates cell cycle progression, spermatogenesis and osteoclastogenesis. Mutations in the CYLD gene is associated with cylindromatosis, multiple familial trichoepithelioma and Brooke-Spiegler syndrome.

Forma física

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Información legal

ExtrAvidin is a registered trademark of Merck KGaA, Darmstadt, Germany

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Producto relacionado

Referencia del producto
Descripción
Precios

Código de clase de almacenamiento

10 - Combustible liquids

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Rajeswara Rao Pannem et al.
Carcinogenesis, 35(2), 461-468 (2013-10-10)
Posttranslational modification of different proteins via direct ubiquitin attachment is vital for mediating various cellular processes. Cylindromatosis (CYLD), a deubiquitination enzyme, is able to cleave the polyubiquitin chains from the substrate and to regulate different signaling pathways. Loss, or reduced
CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes
Sun SC
Cell Death and Differentiation, 17(1), 25-25 (2010)
Hua Ni et al.
Cell death & disease, 15(8), 581-581 (2024-08-10)
The primary cilium behaves as a platform for sensing and integrating extracellular cues to control a plethora of cellular activities. However, the functional interaction of this sensory organelle with epithelial-mesenchymal transition (EMT) during pulmonary fibrosis remains unclear. Here, we reveal
Satoshi Yamashita et al.
Scientific reports, 9(1), 11606-11606 (2019-08-14)
Sporadic inclusion body myositis (sIBM) is the most commonly acquired myopathy in middle-aged and elderly people. The muscle histology is characterized by both inflammation and degeneration, including sarcoplasmic aggregation of TDP-43. Cylindromatosis (CYLD) is a deubiquitinating enzyme that targets Lys63-linked
Dimitrios Papanikolaou et al.
Medicina (Kaunas, Lithuania), 60(6) (2024-06-27)
Chromophobe RCC (ChRCC) carries the best prognosis among all RCC subtypes, yet it lacks a proper grading system. Various systems have been suggested in the past, causing much controversy, and Avulova et al. recently proposed a promising four-tier grading system

Preguntas

Revisiones

Sin puntuación

Filtros activos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico